Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Antimicrobial activities of BMS-284756 compared with those of fluoroquinolones and beta-lactams against gram-positive clinical isolates.

Literature DB >> 11751142

Antimicrobial activities of BMS-284756 compared with those of fluoroquinolones and beta-lactams against gram-positive clinical isolates.

Matteo Bassetti¹, Louise M Dembry, Patricia A Farrel, Deborah A Callan, Vincent T Andriole.

Abstract

The in vitro antibacterial activity of BMS-284756 was compared to those of ciprofloxacin, gatifloxacin, moxifloxacin, ceftriaxone, imipenem, piperacillin-tazobactam, and amoxicillin-clavulanic acid against 492 gram-positive clinical isolates. BMS-284756 was the most-active agent against Streptococcus pneumoniae, Streptococcus viridans, beta-hemolytic streptococci, methicillin-sensitive and -resistant Staphylococcus aureus, methicillin-sensitive and -resistant coagulase-negative staphylococci, and enterococci.

Entities: Chemical Species

Mesh：

Substances：

Year: 2002 PMID： 11751142 PMCID： PMC126992 DOI： 10.1128/AAC.46.1.234-238.2002

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

14 in total

1. Activity and spectrum of BMS 284756, a new des-F (6) quinolone, tested against strains of ciprofloxacin-resistant Gram-positive cocci.

Authors: R N Jones; M A Pfaller; M Stilwell
Journal: Diagn Microbiol Infect Dis Date: 2001-02 Impact factor: 2.803

2. Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756.

Authors: J C Fung-Tomc; B Minassian; B Kolek; E Huczko; L Aleksunes; T Stickle; T Washo; E Gradelski; L Valera; D P Bonner
Journal: Antimicrob Agents Chemother Date: 2000-12 Impact factor: 5.191

3. Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus.

Authors: H M Blumberg; D Rimland; D J Carroll; P Terry; I K Wachsmuth
Journal: J Infect Dis Date: 1991-06 Impact factor: 5.226

4. Antimicrobial activity of gatifloxacin (AM-1155, CG5501), and four other fluoroquinolones tested against 2,284 recent clinical strains of Streptococcus pneumoniae from Europe, Latin America, Canada, and the United States. The SENTRY Antimicrobial Surveillance Group (Americas and Europe).

Authors: B A Odland; R N Jones; J Verhoef; A Fluit; M L Beach
Journal: Diagn Microbiol Infect Dis Date: 1999-08 Impact factor: 2.803

5. Ciprofloxacin-resistant Staphylococcus aureus.

Authors: H Humphreys; E Mulvihill
Journal: Lancet Date: 1985-08-17 Impact factor: 79.321

6. Survey of blood stream infections attributable to gram-positive cocci: frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program. SENTRY Participants Group.

Authors: M A Pfaller; R N Jones; G V Doern; H S Sader; K C Kugler; M L Beach
Journal: Diagn Microbiol Infect Dis Date: 1999-04 Impact factor: 2.803

7. Comparison of three methods for determination of a single MIC of an antimicrobial agent.

Authors: L A Miller; S F Rittenhouse; L J Utrup; J A Poupard
Journal: J Clin Microbiol Date: 1994-05 Impact factor: 5.948

8. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms.

Authors: J M Blondeau; R Laskowski; J Bjarnason; C Stewart
Journal: Int J Antimicrob Agents Date: 2000-02 Impact factor: 5.283

Review 9. In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program.

Authors: R N Jones; M A Pfaller
Journal: Clin Infect Dis Date: 2000-08 Impact factor: 9.079

10. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.

Authors: A Bauernfeind
Journal: J Antimicrob Chemother Date: 1997-11 Impact factor: 5.790

9 in total

9. Antimicrobial activities of garenoxacin (BMS 284756) against Asia-Pacific region clinical isolates from the SENTRY program, 1999 to 2001.

Authors: K J Christiansen; J M Bell; J D Turnidge; R N Jones
Journal: Antimicrob Agents Chemother Date: 2004-06 Impact factor: 5.191

9 in total

Antimicrobial activities of BMS-284756 compared with those of fluoroquinolones and beta-lactams against gram-positive clinical isolates.

1. Activity and spectrum of BMS 284756, a new des-F (6) quinolone, tested against strains of ciprofloxacin-resistant Gram-positive cocci.

2. Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756.

3. Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus.

4. Antimicrobial activity of gatifloxacin (AM-1155, CG5501), and four other fluoroquinolones tested against 2,284 recent clinical strains of Streptococcus pneumoniae from Europe, Latin America, Canada, and the United States. The SENTRY Antimicrobial Surveillance Group (Americas and Europe).

5. Ciprofloxacin-resistant Staphylococcus aureus.

6. Survey of blood stream infections attributable to gram-positive cocci: frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program. SENTRY Participants Group.

7. Comparison of three methods for determination of a single MIC of an antimicrobial agent.

8. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms.

Review 9. In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program.

10. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.

Review 1. In vitro antibacterial activity and pharmacodynamics of new quinolones.

2. Time-kill studies of the antianaerobe activity of garenoxacin compared with those of nine other agents.

Review 3. Alternative strategies for proof-of-principle studies of antibacterial agents.

4. Garenoxacin treatment of experimental endocarditis caused by viridans group streptococci.

5. Postantibiotic effects of garenoxacin (BMS-284756) against 12 gram-positive or -negative organisms.

6. Activities of garenoxacin (BMS-284756) and other agents against anaerobic clinical isolates.

7. The Role of Fluoroquinolones in the Treatment of Skin and Soft Tissue Infection.

8. In vitro activities of a new des-fluoro(6) quinolone, garenoxacin, against clinical anaerobic bacteria.

9. Antimicrobial activities of garenoxacin (BMS 284756) against Asia-Pacific region clinical isolates from the SENTRY program, 1999 to 2001.